Skip to main content
Premium Trial:

Request an Annual Quote


1:00 PM
US Eastern

Sponsored by Millipore Sigma

Development of New Metabolism-Based Multi-Cancer Biomarkers to Detect the Earliest Stages of Cancer

This webinar will address the need for innovation in the early detection of cancer and the approach taken by Elypta, a Swedish cancer detection firm, to develop new metabolism-based biomarkers.

Elypta was funded by the EU Horizon 2020 program to bring the first kidney cancer recurrence test to market. Elypta’s approach is based on profiling glycosaminoglycans — or the GAGome — and developing scores indicative of cancer. At the 2021 American Society of Clinical Oncology conference, a proof-of-concept study across 14 cancer types revealed the broader potential for early detection using the technology, highlighting the sensitivity to stage I disease.

Karl Bergman, CEO of Elypta, will discuss the need for new cancer biomarkers and Elypta’s results highlighting the potential of glycosaminoglycans as a tool in early detection. He will also outline the path Elypta took to develop their research-use-only (RUO) kits, partnering with MilliporeSigma at an early stage to ensure a clear path to large-scale in vitro diagnostic (IVD) manufacturing and enabling the Elypta team to focus their efforts on research and development.

Michael Mitchell, commercial project manager at MilliporeSigma, will discuss the milestones and challenges of MilliporeSigma’s work with Elypta. Mitchell will cover highlights from the set-up, pilot, and engineering phases of Elypta’s RUO cancer detection kit, as well as the preparative work for their IVD offering.

Attendees will learn:

  • Why more biomarkers are needed for the earliest stages of cancer
  • Key aspects and results from the GAGome-based liquid biopsy platform developed by Elypta
  • How a partnership with MilliporeSigma helped Elypta in the development journey

Sponsored by